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Abstract
Background: Marfan syndrome (MFS) is a heritable disorder of connective tissue resulting from pathogenic variants
of the fibrillin-1 gene (FBN1). Neonatal Marfan syndrome (nMFS) is rare and the most severe form of MFS, involving
rapidly progressive cardiovascular dysfunction leading to death during early childhood. The constant enrichment of
the nMFS mutation spectrum is helpful to improve our understanding of genotype–phenotype correlations in the
disease. Herein, we report a novel dominant mutation in exon 26 of FBN1 (c.3331 T > C) in a sporadic case with nMFS.
Case presentation: An 8-month-old Han Chinese girl presented with the classic nMFS phenotype, including prominent
manifestations of bone overgrowth, aortic root dilatation, and multiple cardiac valve dysfunctions. Genetic analysis
revealed that she was heterozygous for a de novo FBN1 missense mutation (c.3331 T > C). The mutation leads to the
substitution of a highly conserved FBN1 cysteine residue (p.Cys1111Arg), which is likely to severely perturb the FBN1
structure because of an alteration of the disulfide bond pattern in the calcium-binding epidermal growth factor-like
(cbEGF) 12 domain. This variant was absent in 208 ethnically matched controls, providing further evidence that it may be
causative of nMFS. An analysis of nMFS-associated mutations from the UMD-FBN1 database indicates that those de novo
mutations altering disulfide bonds or Ca2+ binding sites of the cbEGF domains encoded by exons 25–33, and a lack of
phenotypic heterogeneity may be associated with an increased risk for nMFS.
Conclusion: We diagnosed an infant with rare nMFS showing rapidly progressive cardiovascular dysfunction and
widely systemic features. As the only causal FBN1 mutation identified in the patient, the missense mutation
c.3331 T > C (p.Cys1111Arg) was associated with the severe phenotype of MFS. However, the pathogenicity of the
novel mutation needs further confirmation in other patients with nMFS. Our review of the prominent characteristics of
nMFS mutations relative to classic or incomplete MFS-related mutations will be helpful for the recognition of novel
nMFS-associated variants.
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Background
Marfan syndrome (MFS) (OMIM 154700) is an autosomal
dominant disorder of fibrous connective tissue involving
the ocular, skeletal, and cardiovascular systems. MFS pa-
tients present with clinical variability, in which the rare
neonatal Marfan syndrome (nMFS) has the most severe
presentation in early childhood [1]. The prognosis of
nMFS is very poor, with a mean survival age of only
16.3 months [2]. Valvular insufficiencies and diaphrag-
matic hernias have been associated with shorter survival
in patients diagnosed before the age of 1 year [3].
nMFS has been correlated with a limited number of
mutations in the neonatal region of the fibrillin-1 gene
(FBN1) (OMIM 134797) [4–6]. In the UMD-FBN1 mu-
tations database (http://www.umd.be/), a total of 1,318
different FBN1 mutations for MFS have been included
to date, of which only 59 (4.8 %) including 37 missense
mutations (2.8 %) are associated with nMFS. Here, we
present a novel missense mutation associated with
nMFS, which leads to a cysteine substitution in the
calcium-binding epidermal growth factor-like (cbEGF)
12 domain of FBN1.
Case presentation
An 8-month-old Han Chinese girl, the only child of her
parents, was born full-term weighing 2.60 kg by vaginal
delivery. Her father was 32 years old and her mother
26 years old. She was diagnosed with suspected MFS at
birth caused by the presence of finger and toe arachnodac-
tyly, elbow and knee flexion contractures, a characteristic
‘senile’ facial appearance, and loose skin, so was referred
to the pediatrician. At the age of 8 days, an x-ray of the
bilateral knee and elbow joints showed bone overgrowth
with no apparent abnormalities of the joints or bone sub-
stance. After that, she received continuous follow-up at
the Division of Children’s Healthcare, West China Second
University Hospital, Chengdu, China. During this period,
she was shown to have pectus excavatum, malnutrition,
growth retardation, and feeding difficulties, with vitamin
D levels at the lower end of normal limits; she was there-
fore administered vitamin D3 and calcium, although she
failed to respond to treatment.
At the age of 6 months, she was admitted to hospital with
bronchial pneumonia and then transferred to a pediatric
cardiovascular ward because of a newly found grade 2–3
precordium murmur. On physical examination, in addition
to malnutrition, she was observed to have a ‘senile’ facial
appearance, loose skin, downslanting palpebral fissures,
frontal bossing, downturned corners of the mouth, and
skeletal abnormalities including big ears, micrognathia, ara-
chnodactyly, a pectus deformity, pes planus, and dolicho-
cephaly (Additional file 1). X-ray analysis of her bilateral
calves showed that the margins of the distal tibial and fibu-
lar metaphysis were not smooth, and that the gap around
the ankle was blurred. Cardiac enlargement and pectus
excavatum were confirmed by computed tomography. Elec-
trocardiography (ECG) suggested a sinus rhythm with ab-
normal Q waves in I and aVL leads. Echocardiography
indicated mitral valve prolapse and regurgitation with a
grade 3 insufficiency, tricuspid valve hypertrophy and re-
gurgitation with a grade 1 insufficiency, left atrial chamber
enlargement, and aortic root dilatation at the sinuses of
Valsalva (23 mm, Z > 2) (Fig. 1). Ectopia lentis could not be
determined because of the failure of pupils to dilate during
several ophthalmologic examinations.
Neither parent had experienced any symptoms similar
to those of their daughter, and their ECG examination
and echocardiography were normal. According to the
revised Ghent criteria for the diagnosis of MFS [7], the de-
tected systemic features (scores) of the present patient in-
cluded the wrist and thumb sign (3), pectus excavatum (1),
pes planus (1), facial features (1), skin striae (1), and mitral
valve prolapse (1). These systemic features (score >7) com-
bined with the presentation of severe aortic root dilation
(Z > 2) resulted in a diagnosis of MFS. After 5 days of anti-
biotic therapy administered intravenously for bronchial
pneumonia, the patient recovered and was discharged. She
was advised continuous follow-up at the Pediatric Cardio-
vascular Division to monitor cardiac function.
At the age of 8 months, the patient presented to the
Department of Medical Genetics, West China Hospital,
Chengdu, China. Her mother stated that no disease or con-
dition had potentially affected the pregnancy, including
hypertension, diabetes, thyroid disease, infection, medica-
tion, or toxic exposure. Moreover, the parents are not con-
sanguineous and there is no family history of unexplained
disorders or hereditary disease. After informed consent had
been obtained, peripheral blood samples of the patient and
her parents were collected for genetic testing to identify the
causal FBN1 mutation. All 65 exons of FBN1 and their
splice sites in the patient were sequenced by Sanger se-
quencing. This identified four variants, including a homo-
zygous synonymous variant in exon 15 (c.1875 T >C,
p.Asn625Asn) (rs25458), two heterozygous missense vari-
ants in exon 26 (c.3331 T >C, p.Cys1111Arg) (Fig. 1) and
exon 27 (c.3442C >G, p.Pro1148Ala) (rs140598), and a het-
erozygous intronic variant (c.3464-5G >A) (rs11853943).
Total RNA was extracted from buccal epithelial cells
and Sanger sequencing of the reverse transcriptase (RT)-
PCR product further confirmed the presence of the vari-
ant c.3331 T > C. Direct sequencing of parental PCR
products showed that substitution c.3331 T > C was ab-
sent in both parents, and also from 208 ethnically
matched controls without the MFS phenotype. There
was no evidence of parental mosaicism of the missense
mutation. The patient’s mother was found to be homo-
zygous for the c.3442C > G substitution. At this time, an
echocardiogram of the patient showed a progression of
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mitral valve regurgitation with a grade 3–4 insufficiency.
She was advised of the possibility of cardiovascular sur-
gery if the severe mitral valve insufficiency led to further
ventricular dysfunction. The CARE Checklist of infor-
mation of the case report is available as Additional file 2.
Discussion
The term neonatal Marfan syndrome was first used in
1991 to describe the most severe phenotype of MFS simi-
lar to cases previously known as infantile Marfan syn-
drome, congenital Marfan syndrome, and severe perinatal
Marfan syndrome [1, 8–10]. Recently, it has been sug-
gested that the term neonatal MFS should be replaced by
early onset and rapidly progressive MFS to represent the
most severe features of MFS in early childhood [11]. Of
the 2,088 MFS patients on the UMD-FBN1 mutations
database (last update, 28/08/14), only 80 (3.8 %) were re-
corded as suffering from nMFS, indicating that nMFS is a
rare condition relative to classic and incomplete MFS. Its
incidence rate is therefore far lower than that estimated
for MFS, at 1/5,000–1/10,000 [11]. Although the charac-
teristics of nMFS have been previously discussed [6, 12],
there are currently no diagnostic criteria. In combination
with systemic manifestations, the identification of FBN1
mutations responsible for nMFS is helpful for disease
diagnosis in the absence of any family history [7].
Our patient carries a de novo variant of FBN1, c.3331
T > C, which has not been reported previously. This mis-
sense substitution affects a cysteine residue in the cbEGF
12 domain (p.Cys1111Arg) of FBN1. Moreover, its absence
in more than 200 ethnically matched controls suggested
that it is a causative mutation [7]. It is of note that there is
another missense mutation in the same codon (c.3332G >
A, p.Cys1111Tyr) in the UMD-FBN1 mutations database
leading to incomplete MFS. Although phenotypic variation
of different mutations in the same codon has been observed
Fig. 1 Echocardiograph showing aortic root dilatation at the sinuses of Valsalva (line in-between two asterisks) and the sequencing result showing the
heterozygous missense mutation c.3331 T > C in the patient (arrow)
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in other codons encoding the disulfide bond-related cyst-
eine residue of the cbEGF domain, the phenotypic conse-
quence of the novel mutation in our patient needs further
confirmation in other patients with nMFS. The nMFS diag-
nosis of our patient is supported by the high-degree similar-
ity of clinical features to those reported previously [5, 13].
Most previously identified nMFS-associated FBN1 mu-
tations are known to cluster between exons 24 and 32,
which is the neonatal region of FBN1 [3, 4, 11, 12]. A re-
cent hypothesis to explain this is that some mutations in
the region may cause enhanced proteolytic susceptibility
of FBN1 and loss of function for heparin binding, leading
to a more severe phenotype relative to other mutations re-
sponsible for milder forms of MFS [14]. However, it is still
difficult to predict the correlations between a given muta-
tion in the region and the nMFS phenotype [11]. In recent
years, more nMFS-causative mutations have been identi-
fied which may offer clues for the recognition of others.
Based on information from the UMD-FBN1 mutations
database, we have determined a number of characteris-
tics of nMFS-associated mutations compared with those
of classic and incomplete MFS. First, 92.3 % (60/65) of
nMFS mutations were de novo, which is significantly
higher than the number of de novo classic and incom-
plete MFS mutations (35.3 %, 417/1,181) (Fisher’s exact
test, α = 0.05; P < 0.001). Second, at the genome level,
the distribution of the two types of mutations differs
among FBN1 exons (Pearson’s χ test, α = 0.05; P < 0.001);
in particular, most nMFS mutations (86.4 %, 51/59) cluster
within exons 24–33 while the distribution of mutations
for classic and incomplete MFS is more even with only
17.4 % (221/1274) in the exon 24–33 region (Fisher’s exact
test, α = 0.05; P < 0.001) (Fig. 2). Third, at the protein level,
91.5 % (54/59) of nMFS mutations are located in cbEGF
domains, which is significantly higher than that of muta-
tions for classic and incomplete MFS (71.7 %, 914/1,274)
(Fisher’s exact test, α = 0.05; P < 0.001). Within the domain
cluster of cbEGFs 11–19 encoded by exons 25–33, 47
nMFS mutations are located, of which 43 (91.5 %) affect
the disulfide bond or Ca2+ binding site. This compares
with only 58.2 % (111/191) of classic and incomplete
MFS mutations (Fisher’s exact test, α = 0.05; P < 0.001).
An nMFS genotype–phenotype analysis showed that
most of the mutations (88.4 %, 52/59) present exclu-
sively in patients with nMFS. Further, of all missense
mutations associated with nMFS, only 8.1 % (3/37) also
Fig. 2 Different distributions of neonatal and classic or incomplete Marfan syndrome-associated mutations among FBN1 exons based on the UMD-FBN1
mutations database
Fig. 3 The location and phenotypic heterogeneity of amino acid substitutions in the FBN1 protein associated with neonatal Marfan syndrome, and
the number of such substitutions in patients with MFS based on the UMD-FBN1 mutations database. nMFS, neonatal Marfan syndrome; iMFS, infantile
Marfan syndrome; cMFS, classic Marfan syndrome; icMFS, incomplete Marfan syndrome
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present in patients with classic or incomplete MFS
(Fig. 3). These observations strongly suggest that lim-
ited phenotypic heterogeneity of nMFS-associated mu-
tations is evident, although it should not be ignored
that some mutations can also result in a later onset or
classic presentation of MFS.
A bicuspid aortic valve (BAV) is a common congeni-
tal heart abnormality [15] that appears to be associated
with mutations in FBN1 because of the significantly
higher frequency of these mutations in affected patients
relative to the general population [16, 17]. One of the
FBN1 variants in the current patient, c.3442C > G, has
previously been reported to be a pathogenic mutation
for BAV [18]. In the present study, the patient was a
heterozygote and her mother a homozygote of the vari-
ant. However, echocardiography did not reveal BAV in
either individual, which does not support causality of
this variant for BAV.
Conclusions
The diagnosis of the severe disease nMFS can be aided by
identifying known nMFS-causing variants through con-
tinuous enrichment of the nMFS mutation spectrum. In
the present study, we identified a novel dominant FBN1
mutation, c.3331 T > C (p.Cys1111Arg), which was as-
sociated with the most severe phenotype of MFS. This
finding will be helpful for the clinical diagnosis, pre-
natal diagnosis, and genetic counseling in patients with
the same mutation. Our brief review, based on the lat-
est database information, summarized the distinctive
features of nMFS-associated mutations relative to mu-
tations for classic and incomplete MFS, which will be
valuable for evaluating the pathogenicity of novel FBN1
variants for nMFS.
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